title: The need for transparency and efficiency in reimbursement decisions relating to drugs for rare diseases.
authors.affiliation: Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, ON, Canada (DC)
authors.forename: Douglas A
authors.initials: DA
authors.lastname: Coyle
authors.affiliation: Division of Hematology/Oncology, Sunnybrook Health Sciences Centre, Odette Cancer Center, University of Toronto, Toronto, ON, Canada (MCC)
authors.forename: Matthew C
authors.initials: MC
authors.lastname: Cheung
authors.affiliation: Division of Infectious Diseases, Department of Medicine, Kingston General Hospital and Queen's University, Kingston, ON, Canada (GAE)
authors.forename: Gerald A
authors.initials: GA
authors.lastname: Evans
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D006457:Hemoglobinuria, Paroxysmal / Q000188:drug therapy*; D006801:Humans; D035583:Rare Diseases / Q000188:drug therapy*
chemical_list: D061067:Antibodies, Monoclonal, Humanized